📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 3.2.S — Drug Substance (OBX-319)

Document ID: M3-S
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q

3.2.S Drug Substance — OBX-319

3.2.S.1 General Information

OBX-319 is a bispecific monoclonal antibody (bispecific antibody) developed by Virtual Biopharma Inc. for the treatment of Systemic Lupus Erythematosus (moderate-to-severe active), administered by the subcutaneous route.

Nomenclature and code. OBX-319 is the sponsor development code for a humanised bispecific immunoglobulin G, subclass 1 (IgG1) monoclonal antibody directed simultaneously against two B-lymphocyte surface antigens, CD19 and CD20. The proper (nonproprietary) name is being progressed through the applicable INN/USAN process; throughout this Module the substance is referred to by its development code.

Molecular structure. The molecule is a heterodimeric, full-length IgG1 antibody. One antigen-binding arm engages CD19 and the second arm engages CD20; the two heavy chains carry complementary Fc mutations that enforce correct heavy-chain heterodimerisation (a knob-into-hole–type interface), and the light-chain pairing strategy is designed to suppress mispaired species so that each Fab arm retains its intended single specificity. The intact molecule is an approximately 150 kDa four-chain (two heavy, two light) glycoprotein stabilised by the canonical inter- and intra-chain disulfide bonds of the IgG1 framework, with a single conserved N-linked glycosylation site in each CH2 domain (Asn297-equivalent). The IgG1 Fc is competent for engagement of Fcγ receptors, C1q, and the neonatal Fc receptor (FcRn); the CH2 N-glycan is a determinant of Fcγ receptor–mediated effector engagement and is therefore treated as a control-relevant attribute (3.2.S.3, 3.2.S.4).

General properties. The drug substance is a clear, colourless to slightly yellow aqueous protein solution. It carries the physicochemical properties expected of a humanised IgG1: a defined isoelectric range, a molar extinction coefficient used for concentration determination by UV absorbance at 280 nm, and solubility/viscosity characteristics compatible with a high-concentration subcutaneous presentation. Genetic and phenotypic identity of the producing cell substrate, and the identity of the purified protein, are established as described in 3.2.S.2 and 3.2.S.3.

Mechanism of action (context). Simultaneous, avidity-driven engagement of CD19 and CD20 targets the molecule to the B-lymphocyte lineage across a broad differentiation window (CD19 is expressed from the pro-B stage through to plasmablasts, complementing the more restricted expression of CD20), and Fc effector engagement mediates depletion of circulating and tissue B cells. This dual-antigen, effector-competent design is the basis for the near-complete peripheral CD19-positive B-cell depletion characteristic of the pharmacology programme and is the rationale for the potency and effector-related quality controls described below.

3.2.S.2 Manufacture

The drug substance is a humanised bispecific IgG1 monoclonal antibody produced in a recombinant CHO cell line from a qualified master/working cell bank. Upstream fed-batch cell culture is followed by a platform downstream train (Protein A affinity capture, low-pH viral inactivation, polishing chromatography, viral filtration, and ultrafiltration/diafiltration). Bispecific chain pairing/assembly, glycosylation, and charge heterogeneity are controlled through the process.

Expression / synthesis system. recombinant Chinese hamster ovary (CHO) mammalian cell culture (fed-batch). Manufacture is under GMP from a qualified cell-bank control system with defined in-process controls (3.2.S.2.2-2.6).

3.2.S.2.1 Manufacturer(s). The drug substance is manufactured, tested, and released by Virtual Biopharma Inc. and its designated contract manufacturing organisation(s). The name, address, and responsibility (manufacture, testing, or storage) of each site are tabulated, with the associated establishment registrations and valid GMP status cross-referenced to Module 1. The molecule is regulated as a therapeutic biologic; the marketing application is filed as a Biologics License Application under 21 CFR Part 601.

3.2.S.2.2 Description of Manufacturing Process and Process Controls. Production begins with thaw of a single working cell bank vial and progressive seed expansion, followed by an N-1 seed step and inoculation of the production bioreactor operated as a fed-batch. Defined feeds, temperature, pH, dissolved oxygen, and duration control cell growth, product titre, and the target glycosylation and charge profiles. Harvest is by centrifugation and/or depth filtration with sterilising-grade filtration to yield clarified harvest. The downstream train comprises: Protein A affinity capture; low-pH viral inactivation with defined pH and hold time; one or more polishing chromatography steps (bind-elute cation exchange and/or flow-through anion exchange, and, where used, a hydrophobic-interaction or mixed-mode step) selected to reduce aggregate, host-cell impurities, and product-related variants, including mispaired/homodimeric and half-antibody species arising from the bispecific assembly; small-virus-retentive nanofiltration; and ultrafiltration/diafiltration into the drug-substance formulation buffer with concentration adjustment. Correct bispecific chain pairing and assembly are engineered at the molecule level and confirmed analytically, and the polishing sequence is designed to clear residual mispaired and aggregated species. Each step carries defined operating parameters and in-process controls (3.2.S.2.4). Batch scale, load ratios, and process step yields are described, and the drug substance is stored under the conditions justified in 3.2.S.7.

3.2.S.2.3 Control of Materials. The cell substrate is a recombinant CHO line; a two-tiered master cell bank (MCB) and working cell bank (WCB) system is established, characterised, and tested for identity, viability, and adventitious agents in accordance with ICH Q5A(R2) and Q5D, with genetic stability across and beyond the production age demonstrated per ICH Q5B. Raw materials, media, feeds, buffers, and chromatography resins/filters are controlled to compendial or internal specifications; animal-origin-free sourcing is used wherever feasible, and any animal-derived material carries appropriate adventitious-agent controls. Certificates of analysis and compendial cross-references are provided.

3.2.S.2.4 Controls of Critical Steps and Intermediates. Critical process parameters (for example bioreactor pH, temperature, feed strategy and duration; Protein A load and elution; viral-inactivation pH and hold time; nanofiltration integrity; UF/DF endpoints) are controlled within validated ranges, and in-process controls (titre, bioburden, endotoxin, pH, conductivity, product-related size and charge variants, and step yield) are applied at defined points. Intermediate hold conditions and maximum hold times are qualified. Acceptance limits for critical steps and for any tested intermediates are provided.

3.2.S.2.5 Process Validation and/or Evaluation. Consistency of the commercial process is demonstrated through process performance qualification at the intended scale, supported by studies of impurity clearance (host-cell protein, host-cell DNA, residual Protein A, media components, and product-related variants including mispaired and aggregated species), chromatography resin and membrane lifetime/reuse, and hold-time qualification. Viral clearance is validated per ICH Q5A(R2) using orthogonal, mechanistically distinct steps — low-pH inactivation and small-virus-retentive nanofiltration, with additional partitioning across the chromatography steps — to establish robust reduction of enveloped and non-enveloped model viruses.

3.2.S.2.6 Manufacturing Process Development. The evolution of the process across development is summarised, together with a comparability assessment supporting each significant change (cell line/bank, scale, site, or process). Comparability follows ICH Q5E, using side-by-side physicochemical, structural, biological (dual-binding and potency), and impurity data to demonstrate that pre- and post-change material is comparable and that the changes have no adverse impact on quality, safety, or efficacy.

3.2.S.3 Characterisation

The drug substance is characterised for structure and function. Critical quality attributes are: Dual, arm-specific target binding & potency; Correct bispecific chain pairing / assembly; Aggregation (HMW) & fragmentation; N-glycosylation profile / effector attenuation; Charge variants (deamidation/isomerisation); Host-cell impurities, viral & endotoxin safety.

Primary structure and post-translational modifications. The amino-acid sequence and the identity of each of the four chains are confirmed by intact and reduced/deglycosylated mass analysis and by peptide mapping with high sequence coverage, including verification of N- and C-terminal processing (N-terminal pyroglutamate formation and C-terminal lysine variants). Disulfide-bond connectivity and free-thiol content are mapped, and post-translational modifications such as deamidation, isomerisation, and oxidation at susceptible residues are localised and quantified.

Higher-order structure. Secondary and tertiary structure and conformational stability are assessed by orthogonal biophysical methods (for example far-/near-UV circular dichroism, differential scanning calorimetry, and Fourier-transform infrared spectroscopy), establishing a structural fingerprint used to support comparability.

Glycosylation. The CH2 N-glycan profile is characterised by released-glycan analysis with site-occupancy determination, quantifying afucosylation, high-mannose, galactosylation, and sialylation. Because CH2 glycan structure modulates Fcγ receptor engagement and thereby effector-mediated B-cell depletion, the glycoform distribution is characterised and controlled to keep effector engagement consistent across batches.

Charge and size heterogeneity. Charge variants (acidic and basic species arising from deamidation, isomerisation, C-terminal lysine, and related modifications) are resolved by imaged capillary isoelectric focusing and ion-exchange methods. Size heterogeneity — high-molecular-weight aggregate and low-molecular-weight fragment species — is characterised by size-exclusion chromatography, capillary electrophoresis–SDS (reduced and non-reduced), and orthogonal techniques such as analytical ultracentrifugation and/or field-flow fractionation.

Bispecificity, chain pairing, and assembly. Correct heavy-chain heterodimerisation and light-chain pairing are confirmed, and mispaired species, homodimers, and half-antibody are quantified, using high-resolution and native mass spectrometry and hydrophobic-interaction or other orthogonal separations. Simultaneous engagement of both targets is demonstrated in a bridging/dual-binding format (for example surface plasmon resonance or bio-layer interferometry) confirming that a single molecule can bind CD19 and CD20 concurrently.

Biological characterisation. Arm-specific binding affinities to CD19 and to CD20, Fcγ receptor, C1q, and FcRn binding, and cell-based potency reflecting the effector-mediated B-cell–depletion mechanism are characterised. These data underpin the dual bioassay used for lot release (3.2.S.4).

Impurities. Process-related impurities (host-cell protein, host-cell DNA, residual Protein A, and media/process additives) and product-related impurities/variants (aggregates, fragments, charge and glycation variants, and mispaired/assembly variants) are characterised, and adventitious-agent and endotoxin safety are established, consistent with ICH Q6B and the viral-safety strategy of ICH Q5A(R2).

3.2.S.4 Control of Drug Substance

The drug-substance specification (3.2.S.4.1):

Attribute	Analytical procedure	Acceptance criterion
Appearance	Visual	Clear, colourless to slightly yellow solution
Identity	Peptide map / iCIEF	Consistent with reference standard
Purity (monomer)	SE-HPLC	Monomer >= 95%; HMW <= 5%
Purity (CE-SDS non-reduced)	CE-SDS	Main >= 90%
Charge variants	iCIEF	Within qualified ranges
Potency (dual bioassay)	Cell-based reporter	80-125% of reference
Host cell protein	ELISA	<= qualified limit
Bacterial endotoxins	LAL	NMT 0.5 EU/mg

Analytical procedures are validated per ICH Q2(R2); reference standards are qualified (3.2.S.5).

3.2.S.4.1 Specification. The specification above is established in accordance with ICH Q6B and comprises tests for identity, purity/impurities (size and charge heterogeneity), potency, and safety (host-cell protein and bacterial endotoxins), together with appearance. Identity combines an orthogonal structural test (peptide map) with a charge-based test (iCIEF). Purity captures both aggregate/fragment (size) and, through non-reduced CE-SDS, covalent assembly integrity relevant to the bispecific format. Potency is measured by a cell-based dual bioassay reflecting the intended dual-target, effector-mediated mechanism.

3.2.S.4.2 Analytical Procedures. Each listed method (visual appearance; peptide map and iCIEF identity; SE-HPLC; non-reduced CE-SDS; iCIEF charge variants; cell-based reporter potency; host-cell protein ELISA; and LAL endotoxin) is described with respect to principle, system suitability, and reporting. Additional routine controls (for example bioburden and protein concentration) are applied per the control strategy and process design.

3.2.S.4.3 Validation of Analytical Procedures. Methods are validated in accordance with ICH Q2(R2) for the relevant characteristics (specificity, accuracy, precision, linearity, range, and, where applicable, quantitation/detection limits). The potency bioassay and the host-cell protein immunoassay are validated with attention to their biological/relative nature, and the endotoxin method is validated for interference.

3.2.S.4.4 Batch Analyses. Batch-analysis data for representative clinical, process-validation, and, where available, commercial-scale lots demonstrate conformance to the specification and consistency of the process, and support the acceptance criteria.

3.2.S.4.5 Justification of Specification. Acceptance criteria are justified by manufacturing capability, batch history, stability behaviour, and the levels qualified in the nonclinical and clinical programmes. Numerical limits — monomer >= 95% with HMW <= 5%, non-reduced CE-SDS main >= 90%, potency 80-125% of reference, and bacterial endotoxins NMT 0.5 EU/mg — together with qualified ranges for charge variants and a qualified upper limit for host-cell protein, provide assurance of consistent quality, potency, and patient safety across the product lifecycle.

3.2.S.7 Stability

Long-term storage at 2-8 C protected from light; a proposed shelf life supported by real-time, accelerated, and stress ICH Q5C/Q1A(R2) data, with defined in-use (room-temperature) and transport-excursion allowances.

The stability programme follows ICH Q5C and Q1A(R2): long-term storage at 2-8 C protected from light, accelerated conditions, and forced-degradation/stress studies (thermal, freeze-thaw, mechanical agitation, photostability per ICH Q1B, and pH extremes) to elucidate degradation pathways and confirm the stability-indicating power of the analytical panel. Stability is monitored with stability-indicating methods — appearance, protein concentration, SE-HPLC (monomer/HMW), non-reduced CE-SDS, iCIEF charge variants, subvisible particulates, pH, and potency by the dual bioassay. The principal degradation routes assessed are aggregation and fragmentation, deamidation/isomerisation-driven charge shifts, and oxidation. Real-time data from the drug-substance container-closure system support the proposed shelf life at 2-8 C, and the defined in-use (room-temperature) and transport-excursion allowances are justified by the accelerated and stress data.

Governing guidelines: ICH Q5A-Q5E, Q6B, Q1A(R2), Q11, M4Q.